血管紧张素转化酶基因I/D多态性与卡托普利疗效和咳嗽不良反应的关系及其可能机制
DOI:
作者:
作者单位:

作者简介:

通讯作者:

基金项目:


A Study on the Association Between the Therapeutic Effect of Captopril,Induced Cough and Angiotensin-Converting Enzyme Gene I/D Polymorphism and Its Possible Mechanism
Author:
Affiliation:

Fund Project:

  • 摘要
  • |
  • 图/表
  • |
  • 访问统计
  • |
  • 参考文献
  • |
  • 相似文献
  • |
  • 引证文献
  • |
  • 资源附件
    摘要:

    目的探讨血管紧张素转化酶基因I/D多态性与卡托普利降压效果、咳嗽不良反应发生率的关系及其可能机制。方法筛选原发性高血压患者186例,检测血管紧张素转化酶基因I/D多态性,按血管紧张素转化酶I/D基因型分为II型、ID型和DD型三组,给予卡托普利降压(25mg,2次/天),治疗8周,每周随访观察患者血压及咳嗽不良反应发生情况,失访20例。紫外法检测治疗前后血管紧张素转化酶水平、放射免疫法检测P物质水平。比较三组降压疗效、咳嗽不良反应发生率、血管紧张素转化酶及P物质水平的差异,并分析其可能的关系。结果三组间治疗前后血压水平及下降幅度、治疗有效率及显效率差异均无显著性。共有68例患者出现咳嗽不良反应,II基因型组咳嗽不良反应的发生率为57.1%,显著高于ID基因型组和DD基因型组(P<0.05)。三组间治疗前后血管紧张素转化酶水平差异显著(P<0.001),在DD基因型组>ID基因型组>II基因型组(P<0.001)。治疗前后P物质水平在II基因型、ID基因型和DD基因型组依次降低,但组间比较差异无显著性。P物质水平与血管紧张素转化酶水平存在显著负相关(r=-0.652,P<0.001)。结论卡托普利的降压疗效与血管紧张素转化酶基因I/D多态性无明显相关。携带血管紧张素转化酶II基因型的患者服用卡托普利后咳嗽不良反应的发生率较其它两型高。血管紧张素转化酶水平较低是高血压病患者出现血管紧张素转化酶抑制剂相关性咳嗽的重要原因,P物质是参与血管紧张素转化酶抑制剂相关性咳嗽不良反应发生的重要物质。

    Abstract:

    Aim To investigate whether the I/D polymorphism of angiotensin converting enzyme gene is associated with the therapeutic effect of catopril and the incidence of induced cough, and to explore the possible mechanism if there is indeed an association between them. Methods The angiotensin converting enzyme genotypes were detected in 186 patients with essential hypertension and were classified as DD, II and ID groups. All the paitents have taken catopril 25 mg Bid for 8 weeks. Except that 20 patients were lost to follow up, all the patients were visited every week to observe the change of blood pressure and the incidence of induced cough. Angiotensin converting enzyme was determined by ultraviolet spectrometry before and after treatment, and substance P was determined by radioimmunoassay. The thepapeutic effect, incidence of induced cough and the difference in angiotensin converting enzyme and substance P were compared among the three genotypes, and the possible correlation was anlyzed. Results There was no distinct difference in the blood pressures before treatment, after treatment, desending range and therapeutic effective power among the three groups (P>0.05). 68 patients presented induced cough. The angiotensin converting enzyme II genotype had an incidence of 57.1%, which was significantly higher than ID and DD genotypes (P<0.05). There was significant difference in the level of angiotensin converting enzyme before treatment among the three groups (P<0.001): DD genotype was much higher than ID and II (P<0.001); and ID genotype was much higher than II (P<0.001). The results after treatment were similar to that before treatment. The trend of the level of substance P was II>ID>DD before and after treatment, but no significant difference was found among them (P>0.05). The substance P was negatively related with angiotensin converting enzyme (r=-0.652, P<0.001). Conclusion There is no distinct conrrelation between the therapeutic effect of captopril and angiotensin converting enzyme gene I/D polymorphism. The patients of angiotensin converting enzyme II genotype have a higher incidence of induced cough after taking captopril. Low level of angiotensin converting enzyme is a key factor of the angiotensin-converting enzyme inhibitor related cough in patients with hypertension, and substance P is an important substance in the occurrence of angiotensin-converting enzyme inhibitor related cough.

    参考文献
    相似文献
    引证文献
引用本文

唐晓鸿,袁洪,李丽军,黄志军,阳国平,邹绚.血管紧张素转化酶基因I/D多态性与卡托普利疗效和咳嗽不良反应的关系及其可能机制[J].中国动脉硬化杂志,2008,16(5):376~380.

复制
分享
文章指标
  • 点击次数:
  • 下载次数:
历史
  • 收稿日期:2008-01-14
  • 最后修改日期:2008-04-02
  • 录用日期:
  • 在线发布日期: